# Zimmer Biomet Holdings, Inc.: overview

ZBH · NYSE · CIK 1136869 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/zbh.md) · [Financials](/companies/zbh/financials.md) · [Filings](/companies/zbh/filings.md) · [Insiders](/companies/zbh/insiders.md)

Latest reported revenue: [$2.18bn](/filings/0001193125-26-335044.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-335044).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,824](/filings/0001193125-25-266884.md) | [2,023 d](/filings/0001193125-26-059853.md) | [1,909](/filings/0001193125-26-201710.md) | [2,077](/filings/0001193125-26-335044.md) | [2,001](/filings/0001193125-25-266884.md) | [2,244 d](/filings/0001193125-26-059853.md) | [2,087](/filings/0001193125-26-201710.md) | [2,177](/filings/0001193125-26-335044.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [15.3%](/filings/0001193125-25-266884.md) | [19.2% d](/filings/0001193125-26-059853.md) | [15.3%](/filings/0001193125-26-201710.md) | [14.4%](/filings/0001193125-26-335044.md) | [17.6%](/filings/0001193125-25-266884.md) | [6.9% d](/filings/0001193125-26-059853.md) | [17.9%](/filings/0001193125-26-201710.md) | [15.0%](/filings/0001193125-26-335044.md) |
| Net margin | % | [13.7%](/filings/0001193125-25-266884.md) | [11.8% d](/filings/0001193125-26-059853.md) | [9.5%](/filings/0001193125-26-201710.md) | [7.4%](/filings/0001193125-26-335044.md) | [11.5%](/filings/0001193125-25-266884.md) | [6.2% d](/filings/0001193125-26-059853.md) | [11.4%](/filings/0001193125-26-201710.md) | [9.1%](/filings/0001193125-26-335044.md) |
| Diluted EPS | $ per share | [1.23](/filings/0001193125-25-266884.md) | not reported | [0.91](/filings/0001193125-26-201710.md) | [0.77](/filings/0001193125-26-335044.md) | [1.16](/filings/0001193125-25-266884.md) | not reported | [1.22](/filings/0001193125-26-201710.md) | [1.03](/filings/0001193125-26-335044.md) |
| Free cash flow | $m | [351 d](/filings/0001193125-25-266884.md) | [455 d](/filings/0001193125-26-059853.md) | [338](/filings/0001193125-26-201710.md) | [328 d](/filings/0001193125-26-335044.md) | [364 d](/filings/0001193125-25-266884.md) | [443 d](/filings/0001193125-26-059853.md) | [323](/filings/0001193125-26-201710.md) | [394 d](/filings/0001193125-26-335044.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [6,827](/filings/0000950170-24-019353.md) | [6,940](/filings/0000950170-25-026604.md) | [7,394](/filings/0001193125-26-059853.md) | [7,679](/filings/0001193125-26-059853.md) | [8,232](/filings/0001193125-26-059853.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [12.6%](/filings/0000950170-24-019353.md) | [10.0%](/filings/0000950170-25-026604.md) | [17.3%](/filings/0001193125-26-059853.md) | [16.7%](/filings/0001193125-26-059853.md) | [13.3%](/filings/0001193125-26-059853.md) |
| Net margin | % | [5.9%](/filings/0000950170-24-019353.md) | [3.3%](/filings/0000950170-25-026604.md) | [13.8%](/filings/0001193125-26-059853.md) | [11.8%](/filings/0001193125-26-059853.md) | [8.6%](/filings/0001193125-26-059853.md) |
| Diluted EPS | $ per share | [1.91](/filings/0000950170-24-019353.md) | [1.10](/filings/0000950170-25-026604.md) | [4.88](/filings/0001193125-26-059853.md) | [4.43](/filings/0001193125-26-059853.md) | [3.55](/filings/0001193125-26-059853.md) |
| Free cash flow | $m | [1,356](/filings/0001564590-22-007160.md) | [1,168](/filings/0000950170-25-026604.md) | [1,291](/filings/0001193125-26-059853.md) | [1,296](/filings/0001193125-26-059853.md) | [1,473](/filings/0001193125-26-059853.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/zbh/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Dodge & Cox](/funds/200217.md) | 2026-06-30 | $2.08bn | 24,124,735 |  | Added +582,035 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.34bn | 15,614,847 |  | Added +274,041 |
| [HARRIS ASSOCIATES L P](/funds/813917.md) | 2026-06-30 | $1.10bn | 12,738,025 |  | Reduced −221,914 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.09bn | 12,634,937 |  | Reduced −158,475 |
| [Capital International Investors](/funds/1562230.md) | 2026-06-30 | $1.05bn | 12,183,614 |  | Added +3,064,392 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $766.3m | 8,877,171 |  | Added +52,044 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $726.7m | 8,441,747 |  | Reduced −208,481 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $458.7m | 5,349,223 |  | Reduced −30,302 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $342.6m | 3,979,860 |  | Added +374,435 |
| [PRIMECAP MANAGEMENT CO/CA/](/funds/763212.md) | 2026-06-30 | $328.6m | 3,816,680 |  | Reduced −90,470 |

## Recent filings

[All 2,072 filings](/companies/zbh/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-08 | 20:30 ET | [8-K](/filings/0001193125-26-385256.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-385256 |
| 2026-08-05 | 20:11 ET | [8-K](/filings/0001193125-26-335108.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-335108 |
| 2026-08-05 | 20:06 ET | [10-Q](/filings/0001193125-26-335044.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335044 |
| 2026-08-05 | 10:30 ET | [8-K](/filings/0001193125-26-333761.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-333761 |
| 2026-06-29 | 20:02 ET | [8-K](/filings/0001193125-26-288390.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-288390 |
| 2026-05-27 | 21:30 ET | [8-K](/filings/0001193125-26-242207.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-242207 |
| 2026-05-12 | 10:30 ET | [8-K](/filings/0001193125-26-218098.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-218098 |
| 2026-05-01 | 21:11 ET | [10-Q](/filings/0001193125-26-201710.md) | Quarterly report, period 2026-03-31 | 0001193125-26-201710 |
| 2026-04-28 | 10:33 ET | [8-K](/filings/0001193125-26-183430.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-183430 |
| 2026-04-28 | 10:30 ET | [8-K](/filings/0001193125-26-183411.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-183411 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-059853.md), filed Feb 20, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/3d042b3d-c19e-441d-a97e-b30847e14cff)

## About the filer

- CIK: 1136869
- Tickers: ZBH
- Exchange: NYSE
- SIC code: 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.